Our result also comes in accordance with a previous clinical study, which was conducted by Khodir et al. on patients with COVID-19 and demonstrated the potential role of nifuroxazide in attenuating sepsis-induced systemic inflammation and multiple organ failure through interruption of TLR-4/inflammasome NLRP3/IL-1β signaling [24]. This evidence concerns the gene IL1B and Multiple Organ Failure.